CogState Ltd (ASX:CGS) today announced it has entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote the CogState Test in Canada. The first commercial sale is expected to occur before the end of 2012.
The partnership between CogState and Merck will provide Canadian physicians with a tool to help them with early detection of cognitive decline in their patients. “We believe that with CogState and Merck working together, Canadian patients can benefit from expanded cognitive assessment capability in the marketplace," said Christian Sauvageau, Vice President of Customer Innovation Solutions for Merck Canada. “This partnership is part of Merck`s ongoing commitment to finding treatments for diseases involving the central nervous system.”
The full ASX release can be read here.